GSK Albenza shortage
Executive Summary
GlaxoSmithKline Albenza (albendazole) shortages due to "manufacturing issues not related to product quality" will be resolved by February, FDA drug shortages website reports Dec. 8. The anthelmintic is approved for neurocysticercosis and hydatid disease caused by tapeworm infections. The orphan indications are estimated to affect about 300 patients per year in the U.S. (1"The Pink Sheet" June 17, 1996, T&G-2)...